Literature DB >> 6776135

Bacteriology of sputum in cystic fibrosis: evaluation of dithiothreitol as a mucolytic agent.

M R Hammerschlag, L Harding, A Macone, A L Smith, D A Goldmann.   

Abstract

Liquefaction and homogenization have been recommended to ensure accurate, representative sputum cultures. We evaluated dithiothreitol (DTT) as mucolytic agent for culturing sputum samples obtained from 79 cystic fibrosis (CF) patients. Liquefaction with DTT was not superior to direct plating of specimens for routine qualitative cultures. Unliquefied sputum cultures failed to direct 3 of 47 Pseudomonas aeruginosa isolates; DTT-treated specimens missed 5 of 13 Candida albicans isolates. Neither treated nor untreated sputum cultures were completely successful in detecting Staphylococcus aureus or Enterobacteriaceae. Since Haemophilus influenzae was recovered from only two qualitative cultures, we could not evaluate the effect of DTT on the receovery of this organism. However, 27 of 29 strains of H. influenzae were inhibited by concentrations of DTT near the recommended final working concentration of 50 micrograms/ml, suggesting that liquefaction might impair isolation of this organism. Liquefaction with DTT permitted quantitative cultures of CF sputum. The predominant pathogen in our CF population was P. aeruginosa; 37 of 43 (86%) patients were colonized with this organism. Median densities of rough and mucoid strains were 3.2 x 10(7) and 4.3 x 10(7) colony-forming units per ml, respectively. Previous oral antistaphylococcal therapy may have accounted for the observed low density of S. aureus (mean density, 3.5 x 10(3) colony-forming units per ml). We conclude that DTT treatment does not improve recovery of organisms from qualitative cultures but does facilitate quantitative studies of S. aureus and P. aeruginosa in CF sputum.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6776135      PMCID: PMC273459          DOI: 10.1128/jcm.11.6.552-557.1980

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Carbenicillin treatment of Pseudomonas pulmonary infection. Use in children with cystic fibrosis.

Authors:  J P Phair; J S Tan; C Watanakunakorn; L Schwab; L W Sanders
Journal:  Am J Dis Child       Date:  1970-07

2.  Diagnostic and therapeutic advantages of serial quantitative cultures of fresh sputum in acute bacterial pneumonia.

Authors:  J K Pirtle; P W Monroe; T K Smalley; J A Mohr; E R Rhoades
Journal:  Am Rev Respir Dis       Date:  1969-12

3.  Use of a pancreatin-trypsin solution for the liquefaction of sputa for routine bacteriological examination.

Authors:  G A Rawlins
Journal:  J Clin Pathol       Date:  1968-07       Impact factor: 3.411

4.  Quantitative bacteriology of sputum.

Authors:  J P Kilbourn; R A Campbell; J L Grach; M D Willis
Journal:  Am Rev Respir Dis       Date:  1968-11

5.  Sputum liquefying agents: a comparative in vitro evaluation.

Authors:  S R Hirsch; J E Zastrow; R C Kory
Journal:  J Lab Clin Med       Date:  1969-08

6.  Value of dilute inocula in cultural examination of sputum.

Authors:  J M Dixon; D C Miller
Journal:  Lancet       Date:  1965-11-20       Impact factor: 79.321

7.  Carbenicillin and gentamicin: pharmacologic studies in patients with cystic fibrosis and pseudomonas pulmonary infections.

Authors:  M I Marks; R Prentice; R Swarson; E K Cotton; T C Eickhoff
Journal:  J Pediatr       Date:  1971-11       Impact factor: 4.406

8.  Quantitative bacteriological analysis of sputum as a test of antibiotic efficacy.

Authors:  V Lorian; P Khavari; N Gray
Journal:  Appl Microbiol       Date:  1967-05

9.  Quantitation of microorganisms in sputum.

Authors:  P W Monroe; H G Muchmore; F G Felton; J K Pirtle
Journal:  Appl Microbiol       Date:  1969-08

10.  Human serum activities against Hemophilus influenzae, type b.

Authors:  P Anderson; R B Johnston; D H Smith
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

View more
  16 in total

1.  Microbiological processing of respiratory specimens from patients with cystic fibrosis.

Authors: 
Journal:  Can J Infect Dis       Date:  1993-05

2.  High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment.

Authors:  B Giwercman; C Meyer; P A Lambert; C Reinert; N Høiby
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

3.  Utility of gram stain in evaluation of sputa from patients with cystic fibrosis.

Authors:  E Sadeghi; A Matlow; I MacLusky; M A Karmali
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

4.  Comparison of four methods for pretreatment of cystic fibrosis sputa.

Authors:  J E Hoppe; J Holzwarth; M Stern
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-11       Impact factor: 3.267

5.  Simple method for quantifying viable bacterial numbers in sputum.

Authors:  A Pye; R A Stockley; S L Hill
Journal:  J Clin Pathol       Date:  1995-08       Impact factor: 3.411

6.  Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis.

Authors:  A Bauernfeind; R M Bertele; K Harms; G Hörl; R Jungwirth; C Petermüller; B Przyklenk; C Weisslein-Pfister
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

7.  Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation.

Authors:  Oana Ciofu; Bente Riis; Tacjana Pressler; Henrik Enghusen Poulsen; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

Review 8.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

9.  Optimum use of selective plated media in primary processing of respiratory tract specimens from patients with cystic fibrosis.

Authors:  G V Doern; B Brogden-Torres
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

10.  Selective pressure of antistaphylococcal chemotherapeutics in favour of Pseudomonas aeruginosa in cystic fibrosis.

Authors:  A Bauernfeind; G Emminger; G Hörl; B Lorbeer; B Przyklenk; C Weisslein-Pfister
Journal:  Infection       Date:  1987 Nov-Dec       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.